The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Malignt neuroleptikasyndrom--sällsynt diagnos med hög dödlighet.

På svenska

Author

Summary, in English

Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal condition characterised by increased body temperature and muscle rigidity in a patient receiving antipsychotic treatment. Diagnosis also requires the presence of two symptoms of autonomic dysfunction and/or leukocytosis and increased creatin kinase. All neuroleptics, including atypical agents, can cause the condition, which is thought to arise from dopamine receptor blockade in the striatum and hypothalamus. Treatment includes withdrawal of the antipsychotic agent, intensive care, and pharmacological therapy with bensodiazepines, bromocriptine and dantrolene, as well as ECT in refractory cases. Significant differential diagnoses are encephalitis, serotonin syndrome, and lethal catatonia. It is thought that NMS, serotonin syndrome, and lethal catatonia constitute a spectrum of a neurobiological condition characterised by dopaminergic hypofunction as well as serotoninergic hyperfunction.

Publishing year

2009

Language

Swedish

Pages

1273-1276

Publication/Series

Läkartidningen

Volume

106

Issue

18-19

Document type

Journal article review

Publisher

Swedish Medical Association

Topic

  • Neurosciences

Keywords

  • Catatonia: diagnosis
  • Neuroleptic Malignant Syndrome: diagnosis
  • Serotonin Syndrome: diagnosis
  • Neuroleptic Malignant Syndrome: mortality
  • Neuroleptic Malignant Syndrome: complications

Status

Published

Research group

  • Translational Neuroendocrinology

ISBN/ISSN/Other

  • ISSN: 0023-7205